Collaborations - Additional Information (Details) $ / shares in Units, € in Millions					1 Months Ended		3 Months Ended		6 Months Ended
	Jan. 18, 2021 USD ($) $ / shares shares	Aug. 31, 2018 USD ($)	Mar. 14, 2018 EUR (€)	Jan. 23, 2017 USD ($)	Jan. 31, 2022	Jan. 31, 2018 USD ($) Antibody Milestone PerformanceObligation	Jun. 30, 2022 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Feb. 12, 2021 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from issuance of common stock, net									$ 48,015,000	$ 129,398,000
Net fair value of shares								$ 285,000
Development milestones achieved							$ 1,000,000.0
Additional development or commercialization milestones achieved							$ 0		$ 0
Lilly Collaborations Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment receivable	$ 40,000,000.0
Issuance of common stock, shares | shares	706,834
Common stock stated purchase price per share | $ / shares	$ 28.295
Proceeds from issuance of common stock, net	$ 20,000,000.0
Fixed consideration	43,500,000										$ 43,500,000
Upfront payment	40,000,000.0
Net fair value of shares	$ 16,500,000
Incyte Collaboration and License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Residual royalty percentage					4.00%
Incyte Collaboration and License Agreement | License and Related Activities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations, transaction price as deferred revenue				$ 152,600,000
Second ONO Research and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment receivable | €			€ 0.7
Payment to compensate research services | €			0.3
Over time payment for full time equivalent funding | €			€ 0.2
Simcere Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of bispecific antibodies under collaboration and license agreement | Antibody						3
Non-refundable upfront payment received						$ 2,750,000
Collaborations, transaction price as revenue						$ 2,750,000
Milestone payments received		$ 1,800,000
Number of milestones achieved | Milestone						3
Simcere Collaboration and License Agreement | License and Performance | Research and Development
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of performance obligation | PerformanceObligation						3